Vimian Group AB (publ) (VIMGF) announced a strong Q1 2026, with Specialty Pharma, Veterinary Services, and Diagnostics segments all achieving double-digit growth, outperforming the global animal health market. The company also expanded its portfolio through the acquisitions of Italian diagnostics firm I-Vet and Danish clinic group Favna, adding approximately EUR 10 million in annual revenues.
READ MORE FROM SEEKING ALPHA
Vimian Group AB (publ) (VIMGF) has reported a robust start to 2026, showcasing significant momentum across its key segments during its Q1 earnings call. Group CEO Alireza Tajbakhsh, alongside CFO Carl-Johan Zetterberg Boudrie, highlighted the company's impressive performance, with three out of its four segments—Specialty Pharma, Veterinary Services, and Diagnostics—achieving double-digit growth. This growth significantly outpaced the broader global animal health market, signaling strong market penetration and effective business strategies.
Tajbakhsh emphasized the importance of Q1 as an active period for industry and client engagement, providing valuable insights into customer sentiment. The positive feedback from veterinarians at various events appears to be directly reflected in the company's financial results. Further bolstering its market position, Vimian Group successfully completed two strategic acquisitions during the quarter. These include I-Vet, an Italian diagnostics company, and Favna, an innovative clinic group based in Denmark. These acquisitions are projected to contribute an additional EUR 10 million in annual revenues, expanding Vimian's footprint and capabilities within the rapidly evolving animal health sector.
